Mr. Huff was the Chief Executive Officer of Ergo Science Corporation, a biopharmaceutical company based in Boston, Massachusetts that developed neurotransmitter-modulating drugs for the treatment of type II diabetes and obesity. Mr. Huff joined Ergo as its first business executive and, under his leadership, Ergo progressed from seed capital to initial public offering in 39 months. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

Dr. Abrahams was the successor to Mr. Huff as the CEO and President of Ergo Science Corporation. From 1972 until 1994, Dr. Abrahams held various scientific, quality assurance, and regulatory affairs positions with Baxter International Incorporated, an international healthcare company. From 1990 until 1994, Dr. Abrahams was a corporate vice president and corporate officer with Baxter International, responsible for quality and regulatory affairs. Dr. Abrahams received a B.S. in pharmacology from the University of Illinois and a Ph.D. in pharmacology and experimental therapeutics from Loyola University in Chicago, Illinois.

Ms. DeYoung brings 13+ years of experience in the pharmaceuticals business. Her roles have included business development, portfolio and project management, commercial operations and management consulting in biotech firms as well as mid-size and large pharmaceutical companies in the US and abroad. Most recently, she served as Vice President, Business Development for ODC Therapy with responsibilities for licensing, alliance management and commercialization planning. Prior to ODC, she held US and global positions at EMD Pharmaceuticals, the U.S. subsidiary of Germany-based Merck KGaA. Ms. DeYoung began her career in the pharmaceuticals business with Accenture. She received a B.S. degree in Chemistry and Mathematics from Southwestern University and an MBA from the University of Texas.

Dr. Hurwitz holds board certifications in Pediatrics, Pediatric Hematology and Oncology, and Hospice and Palliative Medicine. He is well-versed in clinical medicine and directed a Pediatric Oncology program for several years followed by developing and directing a Pain and Palliative Care Program both at the Maine Medical Center in Portland, Maine. He has experience in the development, implementation, analysis and reporting of clinical research trials. Dr. Hurwitz graduated from the University of Texas Southwestern Medical School, completed Pediatric training at Duke University Medical Center, and subspecialty training at the Johns Hopkins Hospital and the Dana-Farber Cancer Institute.

Mr. Kral joined Reata from the University of Texas Southwestern Medical Center at Dallas (UT Southwestern), where he was Associate Director for Venture Development. At UT Southwestern, he played a leading role in assembling Reatas project portfolio and developing its business plan. Before joining UT Southwestern, Mr. Kral was in positions of increasing responsibility in research, market and competitive analysis, product development and business development at NPS Pharmaceuticals in Salt Lake City. His last position at NPS was as Director of Business Development. Mr. Kral has B.S. and M.S. degrees in biology from Texas Tech University, and received his M.B.A. from the David Eccles School of Business at the University of Utah.

Leveraging her 15+years of pharmaceutical industry experience, Ms. Krauth provides strategic and operational support to ensure projects remain on track to deliver maximum commercial value. Prior to joining Reata, Ms. Krauth was President and co-founder of DrugVoice LLC, a market research and consulting company serving leading pharmaceutical companies. Additionally, she has many years of experience with a leading strategy consulting firm, concentrating on pharmaceutical project/portfolio management and commercialization. Ms. Krauth holds an M.B.A. degree in Strategic Management and Health Care Management from The Wharton School of the University of Pennsylvania and is a cum laude graduate of Rice University with a degree in Biochemistry.

Dr. Meyer's primary role is to develop and implement strategies to move product candidates expeditiously through all stages of development. His duties include overseeing all preclinical development, determining relevant primary and surrogate endpoints for clinical studies, and developing clinical strategies for the drug candidates. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Mr. Mitchell joined Reata in 2008, bringing to the management team over 30 years of experience in chemistry, regulatory affairs, and quality assurance. He joined the organization from Actelion Pharmaceuticals U.S. (South San Francisco, CA). Mr. Mitchell was previously Director of Regulatory Affairs at Biogen Idec (La Jolla, CA) from 2000 to 2004, playing a key role in the commercialization of Zevalin®, the first radioimmunotherapy approved for the treatment of non-Hodgkin's lymphoma. He has held laboratory and regulatory management positions at The Upjohn Company (now part of Pfizer), Bayer, and several early stage biotechnology companies where he was responsible for developing the infrastructure for regulatory affairs and quality assurance. Mr. Mitchell received a B.S. in Chemistry from Mississippi College.

Barbara has over 20 years of clinical research experience in the site, CRO and sponsor environments. She has held clinical, training and regulatory positions during the previous 10 years at MedTrials, Inc. where she most recently held the positions of Vice President, Compliance and Regulatory Affairs and Vice President, Clinical and Regulatory. She is a Registered Nurse in the State of Texas, and has served as Adjunct Faculty for the University of North Texas Health Science Center, Adjunct Clinical Instructor for The University of Texas at Arlington, and as Faculty Associate for The University of Texas Southwestern Medical Center at Dallas. Barbara received a BSN and MSN from the University of Texas at Arlington and is Regulatory Affairs Certified (RAC) through the Regulatory Affairs Professionals Society (RAPS).

Dr. Visnick brings to the management team over 23 years of experience in preclinical research while with Hoffmann LaRoche, Parke-Davis and Pfizer. Dr. Visnick has managed research groups in the inflammatory, metabolic and CNS disease areas, as well as directed the computational sciences group at Pfizer. He received his Ph.D. in organic chemistry from the University of Florida, and spent 2 years as an American Cancer Society Postdoctoral Fellow at the University of Pennsylvania. He has been a member of the American Chemical Society for over 25 years and is currently an Adjunct Professor of Chemistry at the University of Michigan College of Pharmacy.

Dr. Walling brings over 20 years of pharmaceutical development experience to the Reata organization. Dr. Walling joined Reata after making significant contributions at Ferro Pfanstiehl Laboratories where he was Director of Chemical and Process Technology. He was instrumental in assisting the company in establishing a successful Fee for Service business strategy and platform focusing on development and commercial manufacturing of cytotoxic and highly potent active pharmaceutical ingredients. Previously, Dr. Walling held positions of increasing responsibility in research, development and manufacturing operations within ILEX Oncology, Cambrex Corporation and Abbott Laboratories. Dr. Walling has a Ph.D. in Organic Chemistry from Iowa State University with a focus on natural products synthetic chemistry. He also holds a RAC certification from the Regulatory Affairs Professionals Society.

Dr. Wigley is co-inventor of Reata's pioneering protein folding technology platform and is recognized as a leader in the field of protein misfolding and disease. Prior to joining Reata, Dr. Wigley was a Senior Research Scientist in the Department of Physiology, UT Southwestern Medical Center, where he championed the design and development of assays to monitor protein misfolding associated with a variety of pathologies. Dr. Wigley received a B.S. in Biochemistry and a Ph.D. in Chemistry from Texas Tech University. His post-doctoral training was conducted in the Departments of Molecular Genetics and Physiology at UT Southwestern.

Mr. Wilson joined Reata in 2006 and has over 14 years financial management and accounting experience in life sciences-related businesses. From 2003 until 2006 he served as Vice President, Finance & Corporate Controller at Caris Diagnostics, a specialty laboratory company. Previously, he was a Senior Manager in the health-sciences group at Ernst & Young's Dallas office serving clients across the healthcare spectrum from the start-up to IPO phase, to the Fortune 1000. Mr. Wilson holds a BBA in Accounting, an MBA and is a Certified Public Accountant.